Corticotropin

Generic Name: Corticotropin

Brand Names: Acthar, Cortrophin

Drug Type: Biotech

CAS Number: 12427-33-7

Unique Ingredient Identifier: K0U68Q2TXA

Overview

Corticotropin (ACTH or adrenocorticotropic hormone) is a polypeptide hormone produced and secreted by the pituitary gland. It is an important player in the hypothalamic-pituitary-adrenal axis.

Background

Corticotropin (ACTH or adrenocorticotropic hormone) is a polypeptide hormone produced and secreted by the pituitary gland. It is an important player in the hypothalamic-pituitary-adrenal axis.

Indication

For use as a diagnostic agent in the screening of patients presumed to have adrenocortical insufficiency. Purified corticotropin for injection is indicated for a variety of allergic and autoimmune conditions.

Associated Conditions

Acute Gouty Arthritis
Allergic Conjunctivitis (AC)
Ankylosing Spondylitis (AS)
Atopic Dermatitis
Chorioretinitis
Choroiditis
Infantile Spasms (IS)
Iridocyclitis
Iritis
Keratitis
Multiple sclerosis exacerbation
Optic Neuritis
Polymyositis
Psoriatic Arthritis
Rheumatoid Arthritis
Rheumatoid Arthritis, Juvenile
Serum Sickness
Stevens-Johnson Syndrome
Systemic Lupus Erythematosus
Anterior eye segment inflammation
Severe Erythema multiforme
Severe Psoriasis
Symptomatic Sarcoidosis
Systemic Dermatomyositis

Crinecerfont Shows Promise in Pediatric Congenital Adrenal Hyperplasia Across All Patient Subgroups

14 days ago

Phase 3 CAHtalyst pediatric study demonstrates that crinecerfont (CRENESSITY) effectively reduces glucocorticoid dosing while maintaining or improving androstenedione levels in children with classic congenital adrenal hyperplasia.

Mineralys Therapeutics' Lorundrostat Advances to Phase 2 for Obstructive Sleep Apnea and Hypertension

4 months ago

Mineralys Therapeutics' lorundrostat receives FDA clearance for a Phase 2 trial targeting obstructive sleep apnea (OSA) in hypertensive patients.

Breakthrough Year in Multiple Sclerosis Research: Key Advances and Treatment Milestones in 2024

5 months ago

2024 marked significant progress in multiple sclerosis treatment and research, highlighted by the revision of McDonald diagnostic criteria and breakthrough clinical trials. Notable developments included positive results for tolebrutinib in non-relapsing SPMS and promising outcomes for ublituximab in treatment transitions, representing major steps forward in MS care.

FDA Approves Neurocrine's Crenessity (crinecerfont) for Congenital Adrenal Hyperplasia

5 months ago

The FDA has approved Crenessity (crinecerfont) as an adjunctive treatment for congenital adrenal hyperplasia (CAH) in adults and children, marking a significant advancement.

FDA Grants Priority Review to Crinecerfont for Congenital Adrenal Hyperplasia

8 months ago

The FDA has accepted two New Drug Applications for Neurocrine Biosciences' crinecerfont, granting Priority Review for treating classic congenital adrenal hyperplasia (CAH).

Drug Development Updates